Taking stock of the drug industry, from the lab to the medicine chestJanuary 8, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Sen. Sanders, others lawmakers open probe into asthma inhaler makers over pricing, patent maneuvers The lawmakers argued that billions of dollars in inhalers sales are "a direct result of the outrageous prices the companies charge." By Ed Silverman STAT+ | The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma Ambrx develops antibody-drug conjugates, treatments that link powerful chemotherapies to homing devices meant to deliver them to tumors. By Andrew Joseph STAT+ | Florida's gambit to import drugs from Canada: 'a complicated road' ahead "All the details still need to be filled out" said Jane Horvath, a former Merck executive and consultant to states seeking to lower drug costs. By Ed Silverman Mel Evans/AP STAT+ | Merck to acquire Harpoon Therapeutics for $680 million The bolt-on deal comes as Merck's top brass searches for ways to bolster the company's revenue after it loses exclusivity on Keytruda. By Jason Mast STAT+ | At JPM, biotech's most prolific dealmaker sees a rosy 2024 for acquisitions On the sidelines of the JP Morgan Healthcare Conference, dealmaker Eric Tokat of Centerview Partners provided his outlook for the coming year. By Adam Feuerstein STAT+ | Former Sage executives join biotech VC Cure Ventures The VC firm has hired Jeff Jonas, Sage's former chief executive, and Al Robichaud, Sage's former chief scientific officer, as partners. By Allison DeAngelis More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments